Skip to content

Revolution Medicines Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 4, 2026 results vs estimates

Revolution Medicines Inc · E.RVMD.NASDAQ · United States
Use symbol E.RVMD.NASDAQ in our API & Excel add-in to retrieve this data ↓
190.27
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 0%
Trend 0%
Bubble Risk LOW
Realised Volatility (20D) 51.76%

Revolution Medicines Inc Forecast

Revolution Medicines Inc short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is neutral (4 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term NEUTRAL signal. Based on 20-day realised volatility of 51.8% a year, a typical one-standard-deviation range is 176.40–204.14 over a week, 161.84–218.70 over a month and 91.79–288.75 over a year. (Signals as of 1 Nov 2026.)

Revolution Medicines Inc Price Chart

MacroFinance.ai

Revolution Medicines Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Revolution Medicines Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Revolution Medicines Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Revolution Medicines Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Revolution Medicines Inc
P/S
207.02x
Mid-range vs own history
QoQ +181.0%
YoY +303.8%
now 207.015556.25 low209.2 high
ⓘP/S As of 22 Nov 2026.See Revolution Medicines Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Revolution Medicines Inc
P/B
17.03x
Stretched vs own history
QoQ +0.5%
YoY +102.8%
now 17.03019.21 low24.99 high
ⓘP/B As of 22 Nov 2026.See Revolution Medicines Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Revolution Medicines Inc
EV/Sales
191.77x
Mid-range vs own history
QoQ +186.7%
YoY +331.1%
now 191.76849.47 low193.95 high
ⓘEV/Sales As of 22 Nov 2026.See Revolution Medicines Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Revolution Medicines Inc
FCF Yield
-3.5%
Strong vs own history
QoQ +26.3%
YoY −39.2%
now -3.523-5.28 low-2.78 high
ⓘFCF Yield As of 22 Nov 2026.See Revolution Medicines Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Revolution Medicines Inc
Earnings Yield
-4.6%
Strong vs own history
QoQ +14.3%
YoY −36.2%
now -4.5737-6.53 low-3.66 high
ⓘEarnings Yield As of 22 Nov 2026.See Revolution Medicines Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Revolution Medicines Inc
Market Cap
$40.9B
Highest in 5 years
QoQ −7.4%
YoY +205.0%
now 40897.775414,715 low44,292 high
ⓘMarket Cap As of 22 Nov 2026.See Revolution Medicines Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Revolution Medicines Inc
Net Debt
-$3.0B
Low vs own history
QoQ −8.6%
YoY +69.9%
now -3012.282-3,296 low-1,471 high
ⓘNet Debt As of 22 Nov 2026.See Revolution Medicines Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Revolution Medicines Inc
Current Ratio
8.36x
Mid-range vs own history
QoQ −26.5%
YoY +3.8%
now 8.36036.8 low11.38 high
ⓘCurrent Ratio As of 22 Nov 2026.See Revolution Medicines Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Revolution Medicines Inc
Quick Ratio
8.34x
Mid-range vs own history
QoQ −26.7%
YoY +3.6%
now 8.33716.8 low11.38 high
ⓘQuick Ratio As of 22 Nov 2026.See Revolution Medicines Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Revolution Medicines Inc
Interest Coverage
-21.92x
Strong vs own history
QoQ −23.9%
YoY —
now -21.9189-36.65 low-21.92 high
ⓘInterest Coverage As of 22 Nov 2026.See Revolution Medicines Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Revolution Medicines Inc
Debt / Equity
0.27x
High vs own history
QoQ +8.0%
YoY +168.2%
now 0.26610.1 low0.29 high
ⓘDebt / Equity As of 22 Nov 2026.See Revolution Medicines Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Revolution Medicines Inc
Piotroski F-Score
2
Mid-range vs own history
QoQ +100.0%
YoY −33.3%
now 21 low3 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Revolution Medicines Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Revolution Medicines Inc
Altman Z-Score
11.13
Mid-range vs own history
QoQ −19.8%
YoY +7.3%
now 11.12699.16 low26.71 high
ⓘAltman Z-Score As of 22 Nov 2026.See Revolution Medicines Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  15 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  13 members-only factors: Sloan Accruals, Cash-Earnings Gap, Asset Quality Index, Depreciation Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Revolution Medicines Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Revolution Medicines Inc fundamentals: income statement, balance sheet & cash flow

Revolution Medicines Inc reported revenue of $0 and net income of -$1.13bn in FY2025, the year ended 31 December 2025 — net income down 88.5% on the prior year. Free cash flow was -$913.7m. These figures are as reported in the filings, not restated: 9 fiscal years and 33 quarters of history, back to December 2017. 156 FINRA short-interest settlements are published alongside them, back to February 2020.

Revenue (FY2025)
$0
Net income
-$1.13bn
-88.5%
Free cash flow
-$913.7m
-60.9%
Net debt
-$225.0m
Shares short (30 Oct 2026)
13.08m
7.76 days to cover
Revolution Medicines Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue0.00.011.635.429.4
Cost of revenue16.6592.2411.2253.1186.9
Gross profit-16.6-592.211.635.429.4
Research & development978.7592.2423.1253.1186.9
Selling, general & admin.187.1—75.640.630.5
Operating income-1,182.4-689.5-487.2-258.3-188.0
EBITDA-1,090.5-589.0-430.3-239.5-179.7
Interest expense24.20.00.39.70.0
Pre-tax income-1,131.3-600.8-439.9-249.1-187.1
Income tax—-0.8-3.5-0.4-7.3
Net income-1,131.3-600.1-436.4-248.7-187.1

Download Revolution Medicines Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.RVMD.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Revolution Medicines Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Revolution Medicines Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Revolution Medicines Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Revolution Medicines Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Revolution Medicines Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Revolution Medicines Inc (United States)

Revolution Medicines Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Revolution Medicines Inc?
Revolution Medicines Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Revolution Medicines Inc price?
The latest close is 190.27 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Revolution Medicines Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is neutral (2 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is neutral (4 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Revolution Medicines Inc?
20-day realised volatility is 51.8% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 14.9% over a month and 7.3% over a week.
What factors affect Revolution Medicines Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Revolution Medicines Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Revolution Medicines Inc?
58 backtested tactical asset allocation strategies trade Revolution Medicines Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Revolution Medicines Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Revolution Medicines Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Revolution Medicines Inc historical data?
In the Free historical data section of this page: the last 10 years of Revolution Medicines Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Revolution Medicines Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Revolution Medicines Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.RVMD.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20161.2
2026-11-19159.43
2026-11-18159.82
2026-11-17162.69
2026-11-16166.87
2026-11-13172.29
2026-11-12176.35
2026-11-11180.7
2026-11-10193.06
2026-11-09200.15
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.